{"id":"golimumab-glm","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Infections (including serious infections)"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Upper respiratory tract infections"},{"rate":"3-8","effect":"Headache"},{"rate":"<1","effect":"Tuberculosis reactivation"},{"rate":"increased relative risk","effect":"Malignancy risk"}]},"_chembl":{"chemblId":"CHEMBL1201833","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Golimumab binds to and neutralizes TNF-α, preventing its interaction with TNF receptors on immune cells and reducing the inflammatory cascade. This suppresses the pathogenic immune response in autoimmune and inflammatory conditions. By inhibiting TNF-α signaling, it reduces joint inflammation, systemic inflammation, and disease progression in conditions like rheumatoid arthritis and inflammatory bowel disease.","oneSentence":"Golimumab is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine driving immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:12.823Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT03253796","phase":"PHASE4","title":"Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-07","conditions":"Spondyloarthritis","enrollment":323},{"nctId":"NCT01668004","phase":"PHASE4","title":"The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-03","conditions":"Ankylosing Spondylitis","enrollment":101},{"nctId":"NCT02687724","phase":"PHASE4","title":"Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis","status":"UNKNOWN","sponsor":"University College Dublin","startDate":"2016-06","conditions":"Colitis","enrollment":136},{"nctId":"NCT00975130","phase":"PHASE3","title":"Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":3366},{"nctId":"NCT00488631","phase":"PHASE3","title":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2007-09","conditions":"Colitis, Ulcerative","enrollment":1228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Golimumab (GLM)","genericName":"Golimumab (GLM)","companyName":"University College Dublin","companyId":"university-college-dublin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Golimumab is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}